胸腺肽α1预防老年慢性阻塞性肺疾病急性加重的研究  

Thymosin α1 prevents acute exacerbation of chronic obstructive pulmonary disease in elderly patients

作　　者：朱正太 李华[1] 鞠俊强[1] 钱晓武[1] 滕茂蓉[1] 翟月芳 

机构地区：[1]江苏省泰州市人民医院老年医学科,225300

出　　处：《中华全科医师杂志》2009年第12期872-874,共3页Chinese Journal of General Practitioners

摘　　要：目的探讨胸腺肽α1对老年慢性阻塞性肺疾病（COPD）患者急性加重的预防作用及其机制。方法将120例老年COPD急性加重期治疗稳定后的患者随机分成治疗组和对照组，每组各60例。对照组单纯给予临床观察，治疗组给予胸腺肽α1 1．6mg皮下注射，每周2次，共2个月。观察1年，每2周随访一次，并于治疗前、治疗后2个月及1年时检查患者血清CD3、CD4、CD8和IgA、IgG、IgM水平及肺功能。结果在治疗后1年内，治疗组患者再次发生急性加重的间隔时间为（110±48）d，比对照组的（92±47）d明显延长（P〈0．05）；发生急性加重的次数为（2．4±1．1）次，比对照组的（3．1±0．9）次明显减少（P〈0．05）；发作时间为（26±13）d，比对照组的（34±11）d明显减少（P〈0．05）；治疗组患者经治疗后，CD4及CD4／CD8比值明显升高（P〈0．05）。结论胸腺肽α1通过增强患者细胞免疫功能，可有效地预防COPD的急性加重。Objective To investigate the prophylactic effect of thymosin α1 on acute exacerbation of chronic obstructive pulmonary disease （AECOPD） in elderly patients. Methods One hundred and twenty COPD patients were randomized into two groups （n = 60 for each）. Patients in the treatment group received thymosin α1 1.6 mg subcutaneously, 2/week for 8 weeks ; while patients in control group received normal saline instead. Serum CD3, CD4, CD8, IgA, IgG and IgM levers were measured, and the pulmonary function were examined before and 2, 12 months after treatment. Results In treatment group the recurrence interval of AECOPD was extended ; the attack frequency and persistence time of AECOPD were significantly lower in comparison with those of the control group （ P 〈 0. 05 ）. CD4 and CD4/CD8 levels were significantly increased （P 〈 0. 05 ） after treatment of thymosinctl. Conclusion Thymosin α1 can protect acute exacerbation of chronic obstructive pulmonary disease in elderly patients.

关 键 词：胸腺肽素 肺疾病 慢性阻塞性 淋巴细胞亚群 

分 类 号：R563.9[医药卫生—呼吸系统]